<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5034">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121002</url>
  </required_header>
  <id_info>
    <org_study_id>AM-DCG-001</org_study_id>
    <nct_id>NCT02121002</nct_id>
  </id_info>
  <brief_title>Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee</brief_title>
  <official_title>A Multi-Center, Double-Blind, Vehicle-Controlled, Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% in the Treatment of Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sristek Clinical Research Solutions Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amneal Pharmaceuticals, LLC</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the therapeutic equivalence and safety of a generic Diclofenac Sodium Topical
      Gel, 1% with Voltaren® Gel 1% in subjects with osteoarthritis  of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>WOMAC Pain Score</measure>
    <time_frame>Baseline, Week 2 and Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline to week 4 in the Western Ontario McMaster Osteoarthritis (WOMAC) pain score</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1176</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Topical Gel, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voltaren Topical Gel, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Diclofenac Sodium Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Topical Gel, 1%</intervention_name>
    <description>Opaque, white gel</description>
    <arm_group_label>Diclofenac Sodium Topical Gel, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voltaren Topical Gel, 1%</intervention_name>
    <description>Opaque, white gel</description>
    <arm_group_label>Voltaren Topical Gel, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Diclofenac Sodium Topical Gel</intervention_name>
    <description>Opaque, white gel</description>
    <arm_group_label>Vehicle Diclofenac Sodium Topical Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, ambulatory male or non-pregnant female subjects aged ≥ 35 years with a
             clinical diagnosis of OA of the knee.

          -  Had an X-ray of the target knee, taken no more than 1 year before baseline, showing
             evidence of OA with Kellgren-Lawrence grade 1-3 disease.

          -  After discontinuing all pain medications for at least 7 days, has at least moderate
             pain on movement for target knee

          -  If female and of child-bearing potential, agree to abstain from sexual intercourse or
             use a reliable method of contraception during the study

          -  Able to tolerate rescue medication with paracetamol/acetaminophen.

        Exclusion Criteria:

          -  Pregnant or lactating or planning to become pregnant during the study period.

          -  X-ray showing evidence of OA with Kellgren-Lawrence grade 4 disease.

          -  History of OA pain in the contralateral knee requiring medication within 1 year prior
             to screening.

          -  After discontinuing all pain medications for at least 7 days, has a baseline score of
             ≥20 mm on a 0-100 mm Visual Analog Scale (VAS) for the contralateral knee immediately
             prior to randomization.

          -  History of secondary OA, rheumatoid arthritis, chronic inflammatory disease or
             fibromyalgia.

          -  History of asthma, hypertension, myocardial infarction, thrombotic events, stroke,
             congestive heart failure, impaired renal function or liver disease.

          -  History of gastrointestinal bleeding or peptic ulcer disease.

          -  Use of warfarin or other anticoagulant therapy within 30 days of study randomization.

          -  Elevated transaminases at screening.

          -  Use of ACE inhibitors, cyclosporine, diuretics, lithium or methotrexate, within 30
             days of study randomization.

          -  Concomitant use of corticosteroids or use within 30 days of study randomization.

          -  Concomitant acetylsalicylic acid therapy other than a stable low dose used for
             cardiac prophylaxis taken for at least 3 months prior to enrollment and maintained
             throughout the duration of the study.

          -  Known allergy to aspirin or nonsteroidal anti-inflammatory drug

          -  Any other acute or chronic illness that could compromise the integrity of study data
             or place the subject at risk by participating in the study.

          -  Receipt of any drug as part of a research study within 30 days prior to screening.

          -  Previous participation in this study.

          -  Any use between screening and baseline of a treatment or medication that may
             potentially confound study assessment that may potentially confound study assessment
             (e.g. use of topical analgesics or anti-inflammatory drugs).

          -  Recent history of major knee injury or surgery.

          -  Known history of positive HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prayag Shah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amneal Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prayag Shah, MD</last_name>
    <phone>91-8128671400</phone>
    <email>prayags@amnealindia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rajendran, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunshine Hospitals</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gurava Reddy, MD</last_name>
      <phone>+91-40-04455-0000</phone>
      <email>guravareddy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gurava Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pardha Saradhi, MD</last_name>
      <phone>91-94-4060-8752</phone>
      <email>amcorthopaedics@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Pardha Saradhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok Kumar, MD</last_name>
      <phone>91-98-4912-3602</phone>
      <email>Ashok_ortho59@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Ashok Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rathi Orthopedic and Research Centre</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaurav J Kishore Rathi, MD</last_name>
      <phone>91-98-2401-5618</phone>
      <email>drgjrathi@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Gaurav J Kishore Rathi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shir Hatkesh Sarvajanik Tabibi Chikitsha Kendra</name>
      <address>
        <city>Junagadh</city>
        <state>Gujarat</state>
        <zip>362 001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narendra Kothari, MD</last_name>
      <phone>91-28-5265-4652</phone>
      <email>hutkesh.research@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Narendra Kothari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre For Knee Surgery</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bharath Mody, MD</last_name>
      <phone>91-26-5235-3670</phone>
      <email>mail@centreforkneesurgery.com</email>
    </contact>
    <investigator>
      <last_name>Bharath Mody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shree Giriraj Multispeciality Hospital</name>
      <address>
        <city>Rajkot</city>
        <state>Gujurat</state>
        <zip>360007</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harshil Kalaria, MD</last_name>
      <phone>91-99-7988-3331</phone>
      <email>harshalkalaria@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Harshil Kalaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Johns Medical College</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe J Cherian, MD</last_name>
      <phone>91-93-4379-4300</phone>
      <email>cherianjoe71@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joe J Cherian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>757001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surendra U Kamath, MD</last_name>
      <phone>91-98-4427-5231</phone>
      <email>skamath3@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Surendra U Kamath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mysore Medical College</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marula Siddappa, MD</last_name>
      <phone>+91-98-4431-9497</phone>
      <email>gmsortho@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marula Siddappa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Government Medical College, Calicut</name>
      <address>
        <city>Calicut</city>
        <state>Kerala</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravindran, MD</last_name>
      <phone>91-94-4702-3525</phone>
      <email>raveendranmk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ravindran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lata Mangeshkar Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sushil Mankar, MD</last_name>
      <phone>91-94-2210-8284</phone>
      <email>drshmankar@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Sushil Mankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jasleen Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smruti Ramteke, MD</last_name>
      <phone>91-98-2351-4680</phone>
      <email>sramteke@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Smruti Ramteke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malpani Multispeciality Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302023</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajiv Gupta, MD</last_name>
      <phone>-1-94-1498-0697</phone>
      <email>drrajivg77@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rajiv Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospitals</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja Pandian, MD</last_name>
      <phone>91-99-6552-8552</phone>
      <email>madurai@aherf-smo.org</email>
    </contact>
    <investigator>
      <last_name>Raja Pandian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M V Hospital and Research Centre</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226 003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunal Bhalla, MD</last_name>
      <phone>91-94-5090-3602</phone>
      <email>kunalicious_kunal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Kunal Bhalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>April 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
